Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.35 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.35 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399916 | 1.00 | TAAR1 (0.35) | TAAR1MAP3K7NR2C2GSK3BPRKD1 | |
| SCHEMBL6398539 | 0.82 | PSEN1 (0.40) | — | |
| SCHEMBL6398544 | 0.82 | PSEN1 (0.40) | — | |
| SCHEMBL6397920 | 0.80 | TAAR1 (0.33) | TAAR1ALDH1A1POLBHRH3GAA | |
| SCHEMBL6397931 | 0.80 | TAAR1 (0.33) | TAAR1ALDH1A1POLBHRH3GAA | |
| SCHEMBL6398925 | 0.77 | OPRM1 (0.39) | TAAR1GAA | |
| SCHEMBL6399588 | 0.75 | HRH3 (0.36) | TAAR1ALDH1A1POLBHRH3GAA | |
| SCHEMBL6396679 | 0.74 | HRH3 (0.36) | TAAR1ALDH1A1POLBHRH3CREBBP | |
| SCHEMBL6396683 | 0.74 | HRH3 (0.36) | TAAR1ALDH1A1POLBHRH3CREBBP | |
| SCHEMBL6403374 | 0.73 | PSEN1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949585-B2 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1375465-A9 | CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1375479-A1 | PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | CCR1, CCL2, CCR5 | TAAR1 2321/4885MAP3K7 1728/4885NR2C2 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.